

ASH Virtual Meeting & Exposition, December 2-8, 2020

Presentation Schedule for Winship Cancer Institute of Emory University and Emory University School of Medicine Faculty and Trainees



Wednesday, December 2, 2020

Time	Session Type	Abstract #	Presenting Author	Senior Author	Title
8:35 AM - 9:35 AM	Scientific Workshop		Cheryl Maier, MD, PhD (speaker)		Monitoring for Adverse Hemostatic Outcomes at the Population Level

Thursday, December 3, 2020

Time	Session Type	Abstract #	Presenting Author	Senior Author	Title
10:00 AM - 12:00 PM	ASH-a-Palooza		Martha L. Arellano, MD (speaker)		Blood Buddies: Adult Clinical Malignant Hematology

Friday, December 4, 2020

Time	Session Type	Abstract #	Presenting Author	Senior Author	Title
9:10 AM - 9:55 AM	Scientific Workshop		Claudia R. Morris, MD (speaker)		Arginine Metabolome and Pain
11:00 AM - 2:00 PM	Satellite Symposia		Pamela B. Allen, MD, MSc (speaker)		T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL
3:00 PM - 6:00 PM	Satellite Symposia		Sagar Lonial, MD (chair)		Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma
3:00 PM - 6:00 PM	Satellite Symposia		Jeanne Boudreaux, MD (speaker)		New Agents and Therapeutic Strategies in Beta-Thalassemia

Saturday, December 5, 2020

Time	Session Type	Abstract #	Presenting Author	Senior Author	Title
7:30 AM	Oral Abstract Session	30	Beena E. Thomas	Manoj Bhasin, PhD	Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML
8:30 AM	Oral Abstract Session	17	Fuad El Rassi, MD	Ifeyinwa Osunkwo, MD, MPH	Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU
9:30 AM - 11:00 AM	Oral Abstract Session		Sagar Lonial, MD (moderator)		653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data
9:30 AM - 11:00 AM	Oral Abstract Session		Zhengqi Wang, PhD (moderator)		203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Pathogenesis and Immunotherapy
9:30 AM - 11:00 AM	Oral Abstract Session		Ajay Nooka, MD, MPH (moderator)		731. Clinical Autologous Transplantation: Autologous Transplantation: Still the Backbone of Modern Myeloma Therapies
10:45 AM	Oral Abstract Session	86	Moira M. Lancelot, MD	John D Roback, MD, PhD	Characteristics of in Vitro Differentiated Erythrocytes Derived from Human Bmi-1 Extensively Expanded Erythroblasts (E3)
12:00 PM - 1:30 PM	Oral Abstract Session		Tamara P. Miller, MD, MSc (moderator)		903. Health Services Research—Malignant Conditions (Myeloid Disease): Barriers to Cancer Care Delivery in Myeloid Malignancies
12:00 PM - 12:45 PM	Scientific Program		Robert F. Sidonio Jr., MD, MSc (co-chair)		What the Children Can Teach Us: Congenital Immunodeficiencies Shed Light on Immunity, Hematopoiesis, and Cancer - Live Q&A
2:00 PM - 3:30 PM	Oral Abstract Session		Staci D. Arnold, MD, MBA, MPH (moderator)		901. Health Services Research—Non-Malignant Conditions
2:00 PM - 3:30 PM	Oral Abstract Session		Morgan L. McLemore, MD (moderator)		102. Regulation of Iron Metabolism
2:15 PM	Oral Abstract Session	303	Kristina Lai, MPH	Peter A. Lane, MD	10-Year Mortality in Patients with Sickle Cell Disease from a Large Population-Based Cohort
7:00 AM - 3:30 PM	Poster Session	1417	Sagar Lonial, MD	Adam D. Cohen, MD	DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) – 1-Year Outcomes By Prior Therapies
7:00 AM - 3:30 PM	Poster Session	1378	Ankit Kansagra, MD	Sagar Lonial, MD	Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleuceel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
7:00 AM - 3:30 PM	Poster Session	1325	Benjamin G Barwick, PhD	Larry H. Boise, PhD	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma
7:00 AM - 3:30 PM	Poster Session	1514	Pranav R. Santapuram	Jonathon B. Cohen, MD, MS	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
7:00 AM - 3:30 PM	Poster Session	1136	Jason T. Romancik, MD	Jonathon B. Cohen, MD, MS	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma
7:00 AM - 3:30 PM	Poster Session	1592	Ajay Nooka, MD, MPH	Jonathan L. Kaufman, MD	Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
7:00 AM - 3:30 PM	Poster Session	1023	Anthony Ross, MD	Curtis J. Henry, PhD	Obesity Attenuates T-Cell Function Which Impacts the Efficacy of T-Cell Based Immunotherapies in Acute Lymphoblastic Leukemia
7:00 AM - 3:30 PM	Poster Session	1357	Manoj Bhasin, PhD	David E. Avigan, MD	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study
7:00 AM - 3:30 PM	Poster Session	804	Seung Yup Lee	Erin M. Buckley, PhD	Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies

7:00 AM - 3:30 PM	Poster Session	1340	Karen Sweiss, PharmD	Pritesh Patel, MB, ChB	Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients
7:00 AM - 3:30 PM	Poster Session	897	Jiusheng Deng, PhD	John D Roback, MD, PhD	Effective Erythropoiesis from Human iPSC-Derived RBC in Immunodeficient Mice
7:00 AM - 3:30 PM	Poster Session	1591	Robert Andrew Harkins, MD, MS	Christopher Flowers, MD, MS	Modernizing Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma: Consensus Recommendations Using a Modified Delphi-Method Survey

Sunday, December 6, 2020

Time	Session Type	Abstract #	Presenting Author	Winship Collaborator	Title
9:30 AM - 11:00 AM	Oral Abstract Session		Curtis J. Henry, PhD (moderator)		203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hematologic Malignancies and COVID-19
10:30 AM	Oral Abstract Session	368	Elaissa L. Hardy, PhD	Wilbur A. Lam, MD, PhD	STEM Education for Children with Sickle Cell Disease: Unique Educational Outreach Program Taught By Near-Peer Undergraduate Students
2:30 PM	Oral Abstract Session	478	Victor M. Orellana-Noia, MD	Craig A. Portell, MD	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
7:00 AM - 3:30 PM	Poster Session	2008	Jamie Oakley, MD	Wilbur A. Lam, MD, PhD	Incorporating Hemoglobin Levels to Map Leukostasis Risk in Acute Leukemia Using Microvasculature-on-Chip Technologies
7:00 AM - 3:30 PM	Poster Session	2010	Swati S. Bhasin, PhD	Douglas K Graham, MD, PhD	Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling
7:00 AM - 3:30 PM	Poster Session	2389	Ben Watkins, MD	Leslie Kean, MD, PhD	Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic GVHD
7:00 AM - 3:30 PM	Poster Session	1900	Catherine Hughes, PharmD	Glen Lew, MD	Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase
7:00 AM - 3:30 PM	Poster Session	1747	Yvonne Suessmuth, PhD	Amelia Langston, MD	Potent Interaction between CMV Reactivation and Gvhd: Immunologic Evidence for Blunting of CMV-Driven Immune Reconstitution in the Setting of Gvhd
7:00 AM - 3:30 PM	Poster Session	2013	Rafi Kazi, MD	Daniel S. Wechsler, MD, PhD	Characterizing Proteins That Mediate CALM-AF10 Leukemogenesis
7:00 AM - 3:30 PM	Poster Session	2072	Justine M. Kahn, MD, MSc	Sharon M. Castellino, MD, MSc	Survival Varies By Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group
7:00 AM - 3:30 PM	Poster Session	2354	Claire E. Pillsbury	Christopher C. Porter, MD	Siglec-15 Is a Novel Immunomodulatory Protein and Therapeutic Target in Childhood Leukemia
7:00 AM - 3:30 PM	Poster Session	1727	Andrea Nowlin	Peter A. Lane, MD	Healthcare Utilization Among Children and Adolescents with Sickle Cell Disease during the COVID-19 Pandemic
7:00 AM - 3:30 PM	Poster Session	1783	Angela C. Weyand, MD	Robert F. Sidonio Jr., MD, MSc	Bleeding in Patients with Clinically Severe Von Willebrand Disease: Preliminary Results of Athn 9, a Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)
7:00 AM - 3:30 PM	Poster Session	1719	Richard Onalo, MBBS	Claudia R. Morris, MD	Impact of Oral Arginine Therapy on Global Arginine Bioavailability in Nigerian Children with Sickle Cell Anemia and Vaso-Occlusive Pain
7:00 AM - 3:30 PM	Poster Session	1794	Robert F. Sidonio Jr., MD, MSc	Ayesha Zia	Characterization of Hysterectomy in Women with VWD Using Data from a US Medical Claims Database

Monday, December 7, 2020

Time	Session Type	Abstract #	Presenting Author	Senior Author	Title
7:00 AM - 7:45 AM	Education Program		Tamara P. Miller, MD, MSc (panelist)		Improving Symptom Control for Children with Hematological Malignancies - Live Q&A
7:00 AM - 8:30 AM	Oral Abstract Session		Glaivy Batsuli, MD (moderator)		322. Disorders of Coagulation or Fibrinolysis: Hemophilia: Treatment and Inhibitors
7:15 AM	Oral Abstract Session	549	Jonathan L. Kaufman, MD	Peter M. Voorhees	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
8:00 AM	Oral Abstract Session	558	Christopher Ronald Funk	Edmund K. Waller, MD, PhD	Dual Inhibition of PI3KDelta/Gamma during Manufacturing Reprograms Metabolism of CAR T Cells to Enhance Expansion and Cytotoxicity Against CLL
9:00 AM - 10:30 AM	Oral Abstract Session		Manila Gaddh, MD (moderator)		332. Anticoagulation and Antithrombotic Therapy: COVID-19, Obesity and Hemorrhagic Complications
9:00 AM - 9:45 AM	Scientific Program		Shannon Meeeks, MD (chair)		Mechanisms and Modifiers of Bleeding - Live Q&A
11:30 AM - 12:15 PM	Scientific Program		Madhav V. Dhodapkar, MBBS (panelist)		The Immune System in Multiple Myeloma - Live Q&A
11:30 AM - 1:00 PM	Oral Abstract Session		Pamela B. Allen, MD, MSc (moderator)		624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy in T/NK Cell Lymphoma
1:30 PM	Oral Abstract Session	724	Niels Van De Donk, MD	Sagar Lonial, MD	First Results of Iberdomide (IBER: CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
1:30 PM - 2:15 PM	Special Scientific Symposia		Shannon Meeeks, MD (co-chair)		Special Symposium on the Basic Science of Hemostasis and Thrombosis - Live Q&A
1:30 PM - 3:00 PM	Oral Abstract Session		Edmund K. Waller, PhD, MD (moderator)		701. Experimental Transplantation: Basic Biology, Pre-Clinical Models
2:00 PM	Oral Abstract Session	696	Jamie A.G. Hamilton, BS	Curtis J. Henry, PhD	Obesity-Induced Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells Is Mediated By Reduced Chemotherapy Uptake and Interleukin-9 Signaling
2:30 PM	Oral Abstract Session	698	Waitman K. Aumann, MD, MS	Daniel S. Wechsler, MD, PhD	The SIX1 homeobox Gene Is a Novel Therapeutic Target in CALM-AF10 Leukemogenesis
7:00 AM - 3:30 PM	Poster Session	3426	Josh Carlson, MPH, PhD	Ajay Nooka, MD, MPH	Cost-Effectiveness of Implementing Clonoseq NGS-MRD Testing Using the Emory MRD Decision Protocol in Multiple Myeloma
7:00 AM - 3:30 PM	Poster Session	3221	Ajay Nooka, MD, MPH	Sagar Lonial, MD	Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
7:00 AM - 3:30 PM	Poster Session	3224	Sagar Lonial, MD	Andrzej Jakubowiak, MD, PhD	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
7:00 AM - 3:30 PM	Poster Session	2953	Yazeed Sawalha, MD	Jonathon B. Cohen, MD, MS	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis
7:00 AM - 3:30 PM	Poster Session	3470	Sharon M. Castellino, MD, MSc	Kara M. Kelly, MD	Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions
7:00 AM - 3:30 PM	Poster Session	3474	Emily J. Labudde	Katharine E. Brock, MD	Frequency and Timing of Palliative Opportunities in Pediatric Patients with Hematologic Malignancies
7:00 AM - 3:30 PM	Poster Session	3483	Lauren Willis, PharmD	Jonathon B. Cohen, MD, MS	Medical Simulation in Relapsed Follicular Lymphoma Improves Clinical Decision Making of Hematologists/Oncologists
7:00 AM - 3:30 PM	Poster Session	3432	Pratik A. Patel, MD	Tamara P. Miller, MD, MSc	Infectious Outcomes of Pediatric Acute Lymphoblastic Leukemia Patients Presenting with Non-Neutropenic Fever
7:00 AM - 3:30 PM	Poster Session	2684	Megan C. Brown, MD, MSc	Gary Woods, MD	Platelet Function Analyzer-100 Shows Poor Predictive Value for Children with Low VWF and Mild Platelet Function Defects
7:00 AM - 3:30 PM	Poster Session	2632	Sharmila Raghunandan, DO, MPH	Stephen C Nelson, MD	Late Splenic Sequestration: A Consequence of Early Hydroxyurea Use?